IL17A and inflammatory bowel disease: The effects of IL-17A and anti-IL-17A treatment have also been proved in asthma, rheumatoid arthritis, multiple sclerosis, transplant rejection, and inflammatory bowel disease (Chen and Kolls, 2017).